
    
      This trial is conducted as "Advanced medicine" authorized by the Ministry of Health, Labor,
      and Welfare (MHLW) in Japan, and in in conformance with Clinical Trial Act.

      PIb study is a dose-escalation study comprising two dose levels of imatinib mesylate with
      fixed dose of pembrolizumab to evaluate safety and tolerability and identify maximum
      tolerated dose/administered, and determine recommended phase 2 dose (RP2D).

      In PII study, a Simon's minimax two-stage design is employed.The treatment period with the
      combination therapy of both studies will continue every 21 days for up to 33 cycles
      (approximately 2 years) as long as subjects are receiving benefit from treatment and have not
      had disease progression or met any criteria for study withdrawal.
    
  